Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company focused on precision medicines for cancer, and its news flow reflects the evolution of this strategy. Company announcements highlight progress with KOMZIFTI (ziftomenib), an oral menin inhibitor approved in the United States for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
News items for KURA commonly cover regulatory milestones, clinical data and commercial updates. Recent releases describe full FDA approval of KOMZIFTI, its addition to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a Category 2A recommended option for relapsed or refractory NPM1-mutated AML, and the start of U.S. commercial sales. Kura also reports on its collaboration with Kyowa Kirin, including milestone payments tied to clinical and commercial events.
Investors following KURA news can expect detailed coverage of clinical trial readouts from programs such as KOMET-001, KOMET-007 and KOMET-017, which evaluate ziftomenib across newly diagnosed and relapsed or refractory AML, often in combination with regimens like cytarabine/daunorubicin and venetoclax/azacitidine. Additional news addresses the company’s farnesyl transferase inhibitor programs, darlifarnib and tipifarnib, and their activity in solid tumors.
Kura’s press releases also include corporate updates such as financial results, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in scientific and investor conferences. For readers tracking KURA, this news page offers a centralized view of key developments in its precision oncology pipeline, regulatory interactions, collaborations and commercialization activities.
Kura Oncology, Inc. (Nasdaq: KURA) announced acceptance of three abstracts for tipifarnib presentation at the ASCO Virtual Scientific Program scheduled for May 29-31, 2020. Highlights include an oral presentation on the drug's single-agent activity in solid tumors with HRAS mutations, featuring data from the RUN-HN Phase 2 trial on HNSCC patients. Tipifarnib, a farnesyltransferase inhibitor, has Fast Track designation for treating HRAS mutant HNSCC, with prior studies indicating durable anti-cancer activity. The abstracts are accessible on ASCO's website.
Kura Oncology (Nasdaq: KURA) announced the successful closing of its public offering of 10,465,000 shares of common stock at $13.75 per share, raising approximately $143.9 million in gross proceeds. This includes the underwriters' full exercise of their option to purchase an additional 1,365,000 shares. The offering was conducted under an effective shelf registration statement filed with the SEC. Kura aims to advance its portfolio of precision medicines for cancer treatment, including its leading candidate, tipifarnib, for HRAS mutant head and neck cancer.
Kura Oncology, a clinical-stage biopharmaceutical company focused on precision medicines for cancer, will present at the BofA Securities Virtual Healthcare Conference from May 12-14, 2020. CEO Troy Wilson is set to speak on May 12 at 3:40 p.m. ET. The company’s advanced drug candidate, tipifarnib, is undergoing a registration-directed trial for HRAS mutant head and neck squamous cell carcinoma. Another candidate, KO-539, is in a Phase 1/2A trial for relapsed/refractory acute myeloid leukemia. A live audio webcast of the presentation will be available on Kura's website.
Kura Oncology (Nasdaq: KURA) has announced a public offering of 9,100,000 shares of common stock priced at $13.75 per share, expected to generate approximately $125.1 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 1,365,000 shares. Closing is anticipated on May 8, 2020. The offering is conducted under a shelf registration statement filed with the SEC. This initiative aims to support Kura's efforts in advancing precision cancer medicines.
Kura Oncology has announced the commencement of an underwritten public offering of its common stock. The offering is subject to market and other conditions, with the potential for underwriters to purchase an additional 15% of shares. This move follows Kura's effective shelf registration statement, providing for a streamlined public offering process.
SVB Leerink, Cowen, and Credit Suisse are acting as joint bookrunning managers. The exact size and terms of the offering remain uncertain, emphasizing significant market conditions.
Kura Oncology reported Q1 2020 financials, with a net loss of $19.2 million, increasing from $13.9 million in Q1 2019. The company holds $216.9 million in cash, providing operational leverage for upcoming developments. Kura plans to emphasize its farnesyl transferase inhibitor, tipifarnib, for HRAS mutant HNSCC and the menin inhibitor, KO-539, for NPM1-mutant AML. Three abstracts on tipifarnib will be presented at ASCO 2020. Notably, development of the ERK inhibitor, KO-947, has been terminated to focus on more promising programs.
Summary not available.